Quantitative Structure and activity Relationship of 3a, 6a – Dihydro-1H- pyrrolo[ 3,4-c] pyrazole-4,6-dione Derivatives as anti HIV-1 Agents

Yıl 2020, Cilt: 4 Sayı: 1, 32 - 38, 15.06.2020

Ahanonu Saviour Gideon Adamu Shallangwa Adamu Uzaıru

https://doi.org/10.33435/tcandtc.624157

Cited By: 1

Öz

A novel series of 3a, 6a – Dihydro-1H- pyrrolo[ 3,4-c] pyrazole-4,6-dione Derivatives have been reported as better anti-HIV 1 agents. In this study QSAR was carried on a 3a, 6a – Dihydro-1H- pyrrolo[ 3,4-c] pyrazole-4,6-dione Derivatives as anti HIV – 1 agents. Two different variable selection approaches namely: Genetic function approximation and multi linear regression models were used to predict the HIV-1 inhibition activity. The following were obtained after the model was internally validated: squared correlation coefficient (R2) of 0.8823, adjusted squared correlation coefficient (R2adj) of 0.8528 and leave one out (LOO) cross validation coefficient (Q2cv) of 0.7566. The external validation was carried out to confirm the predictive power of the model and R2pred of 0.6901 was obtained. The validated model result above showed that the five descriptors which are GATS6c, VR3_Dze, minHCsats, RDF30m and Eze contributed positively to the activity. The result obtained will be very helpful for designing and synthesizing other derivatives with improved anti-HIV activities.

Anahtar Kelimeler

HIV, AIDS, QSAR, 3a, 6a – Dihydro-1H- pyrrolo

Kaynakça

• [1] P. Zhan, C. Pannecouque, E. X. De Clercq, Anti-HIV drug discovery and development: current innovations and future trends. J. Med. Chem. 59 (2016) 2849-2878.
• [2] R. Di Santo, Inhibiting the HIV integration process: past, present and future. J. med. chem. 51 (2014) 539-566.
• [3] C. M. Farnet, B. Wang, L. Russell, F. D. Bushman, Differential inhibition of HIV-1 preintegration and purified integrase protein by small molecules. Proc. Natl. Acad. Sci. USA 93 (1996) 9742- 9747.
• [4] V. Ravichandran, R. Harish, J. Abhishek, S. Shalini, P. V. Christapher, A. K. Ram, Validation of QSAR models-Strategies and importance, (2011) 511-519
• [5] Guan-Nan Liu, Rong-Hua Luo, Yu Zhou, Xing- Jie Zhang, Jian Li, Liu- Meng Yang, Yong- Tan Zheng and Hong Liu. Synthesis and Anyi-HIV -1 Activity Evaluation for Novel 3a, 6a – Dihydro-1H- pyrrolo[ 3,4-c] pyrazole-4,6-dione Derivatives. (2016).
• [6] E.A. Shola, S.A. Uba, A. Uzairu, A novel QSAR model for the evaluation and prediction of (E)- N’- Benzylideneisonicotinohydrazide Derivatives as the potent Anti- mycobacterium Tuberculosis Antibiotics using Genetic Function Approach. Physical Chemistry Research, 6 (2018) 479-492.
• [7] P. Singh, Quantitative Structure – Activity Relationship study of subsisted – [1,2,4] oxadiazoles as s1p1 Agonists. J. of current Chemical and pharmaceutical series. (2013).
• [8] A. Tropsha. Best practices for QSAR model Development, Validation and Explitation. Mol. Inf. 29 (2010) 476-488.
• [9] E.A. Shola, E.A. Kalen, A. Mustapha, A.Y. Mahmoud, D. Danzarami, Genetic Function Approximation and Multilinear Regression Approach for Activity modelling of ciprofloxacin Derivatives as potential Anti–prostate cancer Agents: A Theoretical Approach. Kenkyu Journal of pharmacy and Health care. 4 (2018) 6- 16.